Drug Profile

Eculizumab biosimilar - Polpharma Biologics

Alternative Names: BOW 080

Latest Information Update: 26 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bioceros
Developer EPIRUS Biopharmaceuticals
Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
Mechanism of Action Complement C5 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Discontinued Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria

13 Jul 2020 Polpharma Biologics acquired Bioceros and changed name to Polpharma Biologics
25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
16 Nov 2015 Early research in Haemolytic uraemic syndrome in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com